192 related articles for article (PubMed ID: 29968419)
1. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
[TBL] [Abstract][Full Text] [Related]
2. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of KDM5A in human cancer.
Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of KDM5A for cancer treatment.
Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Effects of Ir(III)-2
Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
[TBL] [Abstract][Full Text] [Related]
6. Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation.
Li S; He J; Liao X; He Y; Chen R; Chen J; Hu S; Sun J
Cell Biol Toxicol; 2023 Aug; 39(4):1641-1655. PubMed ID: 36112263
[TBL] [Abstract][Full Text] [Related]
7. Identification of a rhodium(iii) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells.
Yang GJ; Zhong HJ; Ko CN; Wong SY; Vellaisamy K; Ye M; Ma DL; Leung CH
Chem Commun (Camb); 2018 Mar; 54(20):2463-2466. PubMed ID: 29367998
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
9. Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
Petronikolou N; Longbotham JE; Fujimori DG
Biochemistry; 2020 Feb; 59(5):647-651. PubMed ID: 31985200
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
11. KDM5A controls bone morphogenic protein 2-induced osteogenic differentiation of bone mesenchymal stem cells during osteoporosis.
Wang C; Wang J; Li J; Hu G; Shan S; Li Q; Zhang X
Cell Death Dis; 2016 Aug; 7(8):e2335. PubMed ID: 27512956
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Dai B; Huang H; Guan F; Zhu G; Xiao Z; Mao B; Su H; Hu Z
Biomed Pharmacother; 2018 Mar; 99():72-80. PubMed ID: 29324315
[TBL] [Abstract][Full Text] [Related]
13. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
14. Group 9 organometallic compounds for therapeutic and bioanalytical applications.
Ma DL; Chan DS; Leung CH
Acc Chem Res; 2014 Dec; 47(12):3614-31. PubMed ID: 25369127
[TBL] [Abstract][Full Text] [Related]
15. A Rhodium(III)-Based Inhibitor of Lysine-Specific Histone Demethylase 1 as an Epigenetic Modulator in Prostate Cancer Cells.
Yang C; Wang W; Liang JX; Li G; Vellaisamy K; Wong CY; Ma DL; Leung CH
J Med Chem; 2017 Mar; 60(6):2597-2603. PubMed ID: 28219005
[TBL] [Abstract][Full Text] [Related]
16. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
[TBL] [Abstract][Full Text] [Related]
18. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism.
Cui J; Quan M; Xie D; Gao Y; Guha S; Fallon MB; Chen J; Xie K
Oncogene; 2020 Jan; 39(5):1140-1151. PubMed ID: 31641207
[TBL] [Abstract][Full Text] [Related]
19. Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells.
Váraljai R; Islam AB; Beshiri ML; Rehman J; Lopez-Bigas N; Benevolenskaya EV
Genes Dev; 2015 Sep; 29(17):1817-34. PubMed ID: 26314709
[TBL] [Abstract][Full Text] [Related]
20. Rhodium(III)-Based Inhibitor of the JMJD3-H3K27me3 Interaction and Modulator of the Inflammatory Response.
Kang TS; Ko CN; Zhang JT; Wu C; Wong CY; Ma DL; Leung CH
Inorg Chem; 2018 Nov; 57(22):14023-14026. PubMed ID: 30375229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
